What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His main research concerns Multiple myeloma, Internal medicine, Surgery, Bortezomib and Oncology.
His Multiple myeloma study improves the overall literature in Immunology.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His study in Surgery is interdisciplinary in nature, drawing from both Placebo and Immunopathology.
Sagar Lonial has researched Bortezomib in several fields, including Proteasome inhibitor and Tolerability.
His studies in Oncology integrate themes in fields like Cancer, Treatment options, Maintenance therapy and Lymphoma.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (4170 citations)
- Guidelines for the use and interpretation of assays for monitoring autophagy (3242 citations)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
What are the main themes of his work throughout his whole career to date?
Sagar Lonial mainly investigates Internal medicine, Multiple myeloma, Oncology, Bortezomib and Lenalidomide.
His Internal medicine study incorporates themes from Gastroenterology, Surgery and Immunology.
His work deals with themes such as Cancer research, Adverse effect, Pharmacology and Dexamethasone, which intersect with Multiple myeloma.
His research integrates issues of Relapsed refractory, Refractory, Clinical trial and Refractory Multiple Myeloma in his study of Oncology.
His Bortezomib study combines topics from a wide range of disciplines, such as Proteasome inhibitor, Progressive disease, Combination therapy and Phases of clinical research.
His work carried out in the field of Lenalidomide brings together such families of science as Regimen, Tolerability and Neutropenia.
He most often published in these fields:
- Internal medicine (57.24%)
- Multiple myeloma (55.37%)
- Oncology (33.88%)
What were the highlights of his more recent work (between 2018-2021)?
- Multiple myeloma (55.37%)
- Internal medicine (57.24%)
- Oncology (33.88%)
In recent papers he was focusing on the following fields of study:
Sagar Lonial mostly deals with Multiple myeloma, Internal medicine, Oncology, Cancer research and Dexamethasone.
In his research on the topic of Multiple myeloma, Survival rate is strongly related with Progression-free survival.
His study in Lenalidomide, Refractory, Adverse effect, Daratumumab and Bortezomib falls under the purview of Internal medicine.
In his study, which falls under the umbrella issue of Lenalidomide, Hazard ratio and Gastroenterology is strongly linked to Regimen.
In the subject of general Oncology, his work in Overall survival is often linked to In patient, thereby combining diverse domains of study.
His research integrates issues of Cisplatin, Cancer cell, Transcription factor, CD38 and Kinase in his study of Cancer research.
Between 2018 and 2021, his most popular works were:
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (129 citations)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (125 citations)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (91 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Dexamethasone are his primary areas of study.
His Multiple myeloma research is multidisciplinary, relying on both Cancer research and Clinical trial.
His research in Refractory, Bortezomib, Adverse effect, Regimen and Survival rate are components of Internal medicine.
His studies in Adverse effect integrate themes in fields like Nausea, Proteasome inhibitor and Gastroenterology.
His research in Oncology intersects with topics in MEDLINE, Standard of care, Elotuzumab, Proportional hazards model and Transplantation.
His work in Lenalidomide tackles topics such as Interim analysis which are related to areas like Pembrolizumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
